Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular

of clopidogrel and modified-release dipyridamole, having considered evidence on the nature of occlusive vascular events and peripheral arterial disease and the value placed on the benefits of clopidogrel and modified- release dipyridamole by people who have had an occlusive vascular event or are at risk of one, those who represent them, and clinical specialists. It also took into account the effective use of NHS resources. 4.3.2 The Committee discussed current clinical management for the prevention of occlusive vascular events. The Committee heard from clinical specialists that they would value clear, straightforward guidance so that treatment could be started at the earliest possible point, when the risk of recurrent events is highest. Patient experts explained that treatment with clopidogrel or modified-release dipyridamole plus aspirin was an important part of treatment for the prevention of occlusive vascular events but is just 1 part of a wider programme of management involving both pharmacological and non-pharmacological treatment. The Committee heard from the patient experts that people are often on a number of treatments and would value a reduction in the number of tablets that need to be taken. The Committee heard from the patient experts that they considered that clopidogrel had fewer severe side
